Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis

Abstract

IFN-β therapy has a central place in the management of relapsing multiple sclerosis, as demonstrated by the pivotal studies of three IFN-β treatment regimens. However, questions remain concerning the optimal choice of preparation and dose regimen. The benefit−risk ratio for a given preparation is an important consideration in optimising treatment for an individual patient. Of the three IFN-β preparations currently available, all have shown benefit on activity measures (relapses and active lesions apparent on magnetic resonance imaging), while benefit on progression measures (disability and total lesion burden) has been less consistent. Available data across studies suggest that dose and/or dose frequency are important determinants of efficacy, a finding supported by direct comparative data on different IFN-β preparations. The added benefit of high-dose, high-frequency IFN-β therapy is not achieved at the cost of compromised safety or tolerability, indicating that three-times-weekly treatment offers a superior benefit−risk ratio to once-weekly treatment. The potential advantages of IFN-β therapy may be enhanced by regular monitoring of efficacy and safety in order to maintain patients on therapy beyond the first few months when side effects are most apparent.

• benefit–risk ratio
• evidence-based medicine
• IFN-β
• relapsing multiple sclerosis